Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | AHR | P35869 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.30 |
| ▸ | S100A4 | P26447 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL207931 | 0.91 | CYP2A6 (0.32) | CYP2A6ALOX15AHRTRPA1NOS3 | |
| SCHEMBL209366 | 0.73 | S100A4 (0.42) | HSP90AA1TLR9S100A4 | |
| SCHEMBL208048 | 0.73 | S100A4 (0.42) | HSP90AA1TLR9S100A4MAPK1TDP1 | |
| SCHEMBL22028030 | 0.71 | CYP3A4 (0.38) | ALOX15ALDH1A1TDP1 | |
| SCHEMBL3651489 | 0.67 | METAP2 (0.39) | NOS3NOS1NOS2BACE1 | |
| SCHEMBL209193 | 0.66 | AHR (0.40) | AHR | |
| SCHEMBL2863 | 0.66 | — | — | |
| SCHEMBL5744139 | 0.64 | TSHR (0.48) | S100A4ALDH1A1MAPK1TDP1 | |
| SCHEMBL3103046 | 0.63 | NQO2 (0.39) | CYP2A6ALOX15ALDH1A1MAPK1TDP1 | |
| SCHEMBL23233885 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1925611-B1 | OPTICALLY ACTIVE DIAMINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | DAIICHI SANKYO CO LTD (JP) | 2016-04-13 | — | — | EP | disclosed |
| EP-2431370-B1 | Monoacylated 1,2-diaminocycloalkanes | DAIICHI SANKYO CO LTD (JP) | 2013-06-19 | — | — | EP | disclosed |
| EP-1577301-B1 | Antithrombotic diaminocyclohexane derivatives | DAIICHI SANKYO CO LTD (JP) | 2012-09-12 | — | — | EP | disclosed |
| EP-2431370-A1 | Monoacylated 1,2-diaminocycloalkanes | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2012-03-21 | — | — | EP | disclosed |
| US-8088796-B2 | Triamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-01-03 | — | — | US | disclosed |
| US-20110312990-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
| US-8058440-B2 | Process for producing 5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxylic acid | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-11-15 | — | — | US | disclosed |
| EP-2343290-A1 | Diamine derivatives as factor X inhibitors | Daiichi Sankyo Company, Limited (JP) | 2011-07-13 | — | — | EP | disclosed |
| US-7935824-B2 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2011-05-03 | — | — | US | disclosed |
| US-20110077266-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-31 | — | — | US | disclosed |
| EP-1415992-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | disclosed |
| EP-1270557-A1 | ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-01-02 | — | — | EP | disclosed |
| US-5360700-A | Single stabilizing step, magenta and cyan couplers, ferric salt of organic acid | KONICA CORPORATION (JP) | 1994-11-01 | — | — | US | disclosed |
| US-5091293-A | High speed, storage stability | FUJI PHOTO FILM CO., LTD. (JP) | 1992-02-25 | — | — | US | disclosed |
| US-4952485-A | HIGH PHOTOSENSITIVITY | FUJI PHOTO FILM CO., LTD. (JP) | 1990-08-28 | — | — | US | disclosed |
| US-4880725-A | INTENSIFIED DEVELOPMENT | FUJI PHOTO FILM CO., LTD. (JP) | 1989-11-14 | — | — | US | disclosed |
| US-4840877-A | MAGNETA DYE FORMING COUPLER | FUJI PHOTO FILM CO., LTD. (JP) | 1989-06-20 | — | — | US | disclosed |
| US-4820623-A | LAYER CONTAINING MAGENTA PYRAZOLE DYE-FORMING COUPLER AND A NONDIFFUSING CARBOXYLIC ACID OR SALT; ANTISOILANTS; NONSETTLING; EFFICIENT AUTOMATIC DEVELOPMENT | FUJI PHOTO FILM CO., LTD. (JP) | 1989-04-11 | — | — | US | disclosed |
| US-4791048-A | Color image forming process utilizing substantially water-insoluble basic metal compounds and complexing compounds | FUJI PHOTO FILM CO., LTD. (JP) | 1988-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077266-A1 | Diamine Derivatives | F2, TFPI, F3 | CYP2A6 2519/4885ALOX15 3326/4885AHR 3066/4885 |
| US-20110312990-A1 | Diamine Derivatives | C9, C1S, C1R | CYP2A6 2464/4885ALOX15 824/4885AHR 2824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.